Galmed Pharmaceuticals Ltd. (GLMD) News
Track canonical SquawkNews coverage tagged to GLMD, Galmed Pharmaceuticals Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Galmed Pharmaceuticals Terminates License Agreement
Galmed terminates license agreement
EQUITY | Jul 29, 2026, 08:53 PM UTC
L
GLMD GLMD - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibito
GLMD GLMD - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
EQUITY | Jul 28, 2026, 11:02 AM UTC
H
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro
EARNINGS | Jul 21, 2026, 09:11 AM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC
L
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
EQUITY | Jul 01, 2026, 07:59 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
GLMD Increases Cash Portion
Galmed agrees to increase cash portion of purchase price for Colospan by $800K
EQUITY | Jun 22, 2026, 11:35 AM UTC
M
GLMD Restructures Acquisition Terms
Galmed Pharmaceuticals Ltd. restructures acquisition terms for Colospan Ltd., prioritizing CG-100 European commercialization and shareholder value protection.
EQUITY | Jun 22, 2026, 11:03 AM UTC